Home LiteratureArticle Details
PMID: 15701829 Published · ppublish English Comparative Study Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.

Plasma adiponectin and gastric cancer.

Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H

Abstract

Recently, increased body weight has been associated with an increased risk of cancers at multiple specific sites, including gastric cancer. Adiponectin is a peptide hormone secreted by adipose tissue, affecting the proliferation and insulin sensitivity of various types of cells. Moreover, the circulating level of adiponectin has been reported to be inversely related to body mass index. Fasting plasma levels of adiponectin were determined in 75 patients with gastric cancer and 52 healthy controls using an ELISA. In these patients, we analyzed the association between plasma adiponectin level and gastric cancer risk as well as various clinicopathologic characteristics. Plasma adiponectin level was significantly lower in patients with gastric cancer than in healthy controls (9.1 +/- 6.2 versus 13.3 +/- 9.4 ng/mL, P < 0.01) and showed a significant modest inverse relation with the gastric cancer (odds ratio, 0.92; 95% confidence interval, 0.85-0.97; adjusted odds ratio, 0.89; 95% confidence interval, 0.84-0.95], although body mass index was not different. In addition, adiponectin level was extremely low in patients with upper gastric cancers (upper, 5.5 +/- 4.1 ng/mL; middle, 9.7 +/- 6.4 ng/mL; lower, 10.7 +/- 4.1 ng/mL; P = 0.012). Furthermore, adiponectin level tended to decrease as the tumor stage increased (stage I, 9.9 +/- 6.9 ng/mL; stage II, 8.7 +/- 5.5 ng/mL; stage III, 8.6 +/- 4.1 ng/mL; stage IV, 5.2 +/- 6.2 ng/mL; P = 0.34). Interestingly, in 32 patients with undifferentiated cancer, serum adiponectin showed a negative correlation with pathologic findings such as tumor size, depth of invasion, as well as tumor stage (P < 0.05), but no correlation in the remaining 43 patients with differentiated cancer. Our results suggest that a low plasma adiponectin level is associated with an increased risk for gastric cancer and raise the possibility that adiponectin has a potential role in the progression of gastric cancer, especially in undifferentiated type cancers in the upper stomach.

MeSH Terms
Adenocarcinoma/blood,etiology Adiponectin Body Mass Index Carcinoma, Signet Ring Cell/blood,etiology Case-Control Studies Cell Differentiation Collagen/blood Down-Regulation Fasting Female Gastric Mucosa/metabolism Humans Intercellular Signaling Peptides and Proteins/blood Lymphatic Metastasis/pathology Male Middle Aged Neoplasm Invasiveness/pathology Neoplasm Staging Stomach/pathology Stomach Neoplasms/blood,etiology
Chemicals
Adiponectin Intercellular Signaling Peptides and Proteins Collagen
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Ishikawa Makoto
Department of Surgery, Division of Surgical Oncology, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113-8655, Japan. [email protected]
Kitayama Joji
Kazama Shinsuke
Hiramatsu Takeyuki
Hatano Kenji
Nagawa Hirokazu
Article Info
Journal
Clinical cancer research : an official journal of the American Association for Cancer Research
Abbr.
Clin Cancer Res
ISSN
1078-0432
Published
2005-01-15
Pages
466-72
Language
English
Region
United States
NLM ID
9502500
Subset
IM
Grants
NIA NIH HHS · R01 AG 21418 · United States
NCI NIH HHS · R01 CA 1018447 · United States
NIDDK NIH HHS · T32 DK 07790 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]